The cheapest amendment is the one the design never needed.
Rescue deals with what has already gone wrong. This is the other door: science and operations at one table before the protocol locks, and your own team trained to hold the line after.
Protocol lock is a one-way door.
Before it, a change is a redline. After it, the same change is an amendment with a review board, site contracts, system rebuilds, and reconsent attached. Both doors are open. Only one of them is cheap.
Same decision, two very different prices.
Every item below is the same underlying question. The only variable is which side of the lock it gets asked on.
- Eligibility reopened as a substantial amendment
- Enrolled participants reconsented
- Sites added because the first list did not enroll
- Enrollment shortfall found once the window is gone
- Change orders traced back to a scope written loosely
- Systems and training rebuilt to match the new version
- Draft criteria tested against real patient populations
- Visit burden and washout checked against actual practice
- Sites ranked on verified counts, not survey answers
- Enrollment forecast built from data, not from optimism
- Scope, assumptions, and unit costs fixed before the price
- One governed plan the sponsor, CRO, and sites all hold
Right the First Time is not a slogan on this page. It is the gate that has to be passed before anybody signs.
Amendments are not all unavoidable. Sponsors themselves judge a share of them preventable.
Regulatory requests and new safety information will always drive protocol change, and no method prevents those. In Tufts CSDD benchmarking, sponsors and CROs reviewing their own amendments judged 23 percent completely avoidable and a further 22 percent somewhat avoidable, naming protocol design flaws, narrative errors, and infeasible eligibility criteria among the causes. A later Tufts study puts the avoidable share lower. That preventable slice, whatever its exact size in your portfolio, is the category a pre-lock gate can reach.
Protocols now amended
of Phase I to IV protocols carry at least one substantial amendment, up from 57 percent in 2015. The mean number of amendments per protocol has climbed 60 percent to 3.3.
Need-to-amend to final approval
Average time from identifying the need to amend through the last oversight approval. Sites operate on divergent protocol versions for a mean of 215 days across that window. This is the full approval window rather than schedule time lost outright.
Arrival before the first dose
In Tufts CSDD benchmarking, nearly one third of amendments were implemented before the first study volunteer received the first dose. Later Tufts work measures against first patient first visit and reports a smaller share. On either measure, a meaningful block of amendments arrives before a single patient is dosed, which is the window a design gate can reach.
Call before the protocol locks and the work is preventing the amendment. Call after, and the work is implementing it.
Usually somebody saw it coming. They had no vote.
Design error is rarely a competence failure. It is a sequencing failure: criteria are set, and the functions that know the enrollment will not work are consulted afterward. SET changes the order.
One table, before the protocol closes.
In prior roles the principal chaired Study Execution Team advisory committees at a global biopharmaceutical sponsor, spanning Medical Affairs, HEOR, Clinical Pharmacology and Exploratory Development, and Pharmacovigilance, aligning methodology, tactics, and technology across the portfolio. On this engagement SET names the sponsor-side committee, convened inside your organization and chaired until your own people chair it. Where Clinical TrialRx convenes a Study Execution Team of outside specialists for a data-partner program, that is the same method applied to a different seat.
- Clinical development and the medical lead
- Clinical operations and study start-up
- Feasibility and site selection
- Biostatistics and data management
- Regulatory and pharmacovigilance
- Outsourcing, procurement, and finance
- Every inclusion and exclusion criterion, with its purpose stated
- The eligible population the criteria actually describe
- The site list, ranked on verified counts
- Visit burden against real-world practice patterns
- The enrollment forecast, and who owns it
- Scope and assumptions, written before the price
Career figures reflect the principal's documented record in prior roles. Past results do not guarantee future outcomes.
One path from SOW to data lock. The first stop is the one that prevents the rest.
Protocol and SOW reviewed before the price is set
Team, scope, and schedule baselined
Sites, training, and risk log ready
Reviews at every enrollment milestone
Data cleaned and queries closed early
Audit-ready file and lessons learned
The same path governs a rescue. Run it from the first stop, and most of the later stops have less to catch. See the seven reasons sponsors say NO
Many engagements build and then stay. This one is designed to leave.
The deliverable is not a report and it is not a permanent seat. It is a team that holds the metrics without outside help, and people inside your organization who can teach the next group how.
4 to 6 weeks · Fixed scope
One therapeutic area's start-up and protocol workflow mapped end to end. Your own last protocols reviewed to separate the design-driven amendments from the unavoidable ones, and the days and dollars attached to each. The deliverable is a business case built on your numbers, not on a benchmark.
One therapeutic area or one study · Through protocol lock
SET convened and chaired through one protocol to lock. The pre-award SOW stop run live. Your people trained and certified alongside it, and the results measured against the baseline the diagnostic established.
Portfolio-wide · Only after the pilot proves out
Your own chairs running SET across the portfolio, and an internal group able to train the next cohort. Exit is written into the contract and tied to your team holding the metrics agreed in the diagnostic baseline, not to a calendar date.
Durations scale with portfolio size and protocol count. The window for each step is set in the diagnostic, against your own baseline, before anything is committed.
If your next protocol has not locked yet, that is the conversation.
Straight answers, before the first call.
How is this different from trial rescue?
Rescue addresses a study that is already off course, and it is scoped to recovery. Right the First Time is scoped to a study that has not started, or a protocol that has not locked. Same method, same gates, same governance, applied at the point where a change is still a redline rather than an amendment. Sponsors use both: one for the program that is burning now, one for the next three that are still on paper.
When is the right time to bring this in?
While the protocol is in development and before it goes to a review board. The pre-award stop reviews the protocol and the SOW before the price is set, which is also the last point at which scope assumptions can be fixed without a change order. A new program starting, an inspection finding, a CRO transition, or a reorganization in clinical operations are the usual triggers.
Do you replace our CRO, or our internal team?
Neither. On any single study the principal works for one side only, disclosed at engagement. The work is to hold every party to the plan that was bought, and to raise the questions your own functions already wanted to raise before the document closed.
What reduction in protocol amendments is actually claimed?
Only the categories a design gate can reach. Amendments driven by regulatory agency requests, new safety or dose information, or a change in standard of care are not claimed as preventable, because they are not. The target is set against your own baseline during the diagnostic, measured on your own protocols, and agreed before the pilot begins rather than promised in a proposal.
How does the engagement end?
On an exit criterion written into the contract and tied to performance: your team holds the metrics agreed in the diagnostic baseline without outside support, and your own people chair the Study Execution Team. The engagement is designed so that the capability stays when the engagement does not.
Your next study has not started. That is the cheapest day to fix it.
Start with a no-obligation protocol risk call. We will look at where your next protocol is carrying avoidable design and scope risk, which of the seven reasons sponsors say NO is already in play, and what a fixed-scope diagnostic would measure on your own numbers.
Pittsboro, IN 46167